Skip to main content
Psych Congress 2023 Main banner
Back

Master Class
Breakout Session (CME)

Understanding the Role of TAAR1 Agonism in Schizophrenia: Framing the Story around the Whole Patient

Sunday, September 10, 2023
10:30 AM – 11:45 AM CT
Location: Davidson AB

    Speaker(s)

  • Amber Hoberg, PMHNP-BC

    Baptist Health Systems
    Morning Star Family Medicine PLLC

  • Christoph Correll, MD

    Professor of Psychiatry, Chair Child and Adolescent Psychiatry
    (1) The Zucker Hillside Hospital; (2) Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; (3) The Feinstein Institutes for Medical Research; (4) Charité - Universitätsmedizin Berlin
    Zucker School of Medicine at Hofstra/Northwell, New York, USA

Brunch will be served. Seating will be limited.

The session will begin with a unique poster review before expert faculty dive into the lecture. Grab a headset and take a tour of 3 different posters, each highlighting current data on TAAR1 agonists. The lecture portion of this session will begin by discussing the limitations and barriers associated with the use of antipsychotics for schizophrenia whose MOA centers on dopamine D2 binding. Expert faculty will evaluate the mechanism of action and safety/efficacy data associated with TAAR1 agonism in the management of schizophrenia, followed by a discussion of potential clinical implications for TAAR1 agonists and how to identify and educate patients who might benefit from these novel therapies.

Supported by an independent educational grant from Sumitomo Pharma America, Inc. and Otsuka America Pharmaceutical, Inc.

Learning Objectives:

  • Summarize the persistent unmet needs and burdens associated with schizophrenia with regards to disability, morbidity, mortality, and quality of life
  • Assess the treatment limitations associated with conventional antipsychotics for schizophrenia that directly alter postsynaptic D2, including adverse effects, nonresponse, and nonadherence
  • Describe the pathophysiologic role of TAAR1 in schizophrenia and the pharmacodynamics of novel TAAR1 agonists in comparison to current D2 antagonists
  • Evaluate the most recent efficacy, tolerability, and safety data associated with novel TAAR1 agonists and the clinical potential of these emerging agents